Last reviewed · How we verify
Analog or Human Insulin
Human insulin analogs mimic the action of the body's natural insulin, helping to lower blood sugar levels.
Human insulin analogs mimic the action of the body's natural insulin, helping to lower blood sugar levels. Used for Type 1 diabetes, Type 2 diabetes.
At a glance
| Generic name | Analog or Human Insulin |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Human insulin analogs are designed to have a faster onset of action or a longer duration of action compared to natural insulin, allowing for more precise glucose control. They work by binding to insulin receptors on cells, triggering the uptake of glucose from the bloodstream into the cells.
Approved indications
- Type 1 diabetes
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Weight gain
- Allergic reactions
Key clinical trials
- To Evaluate the Change in Glucose Parameters in Adult Patients With Type 1 or Type 2 Diabetes From Europe Using the iCan o3 CGM System for 60 Days Period (NA)
- Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump (PHASE3)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials (NA)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment (PHASE2)
- Comparison of Diabetes Patients - Care Trajectory Versus Convention
- Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Analog or Human Insulin CI brief — competitive landscape report
- Analog or Human Insulin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI